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Crohn's disease (CD) and ulcerative colitis (UC).1 ,2 The global burden of IBD is high, with approximately 3.5 million of people affected in Europe and the United States, and rapidly increasing in newly industrialised countries.3 IBD increases the overall risk of death, 4 and adversely affects quality of life. All these considerations highlight the need for optimal management, comprising highly effective existing and novel medications with an acceptable risk-benefit profile.
Medical treatment of IBD has evolved over the last two decades, particularly since the introduction of biological therapies. Anti-tumour necrosis factor (TNF) α agents (infliximab, adalimumab, certolizumab pegol, and golimumab) were the first monoclonal antibodies used for the treatment of IBD.5 A significant proportion of patients treated with anti-TNF agents experience primary non-response or secondary loss or response.6 -9 Further, there is a risk of relapse after discontinuation 10 and a small increase in the risk of infections and some types of cancer. 11 The evolving understanding of the immunopathogenesis of IBD has led to the development of other biological therapies. Natalizumab was the first antiintegrin monoclonal antibody to be used in the treatment of CD with moderate efficacy; 12, 13 its use in clinical practice was limited by the death of a patient in the ENACT study due to progressive multifocal leukoencephalopathy (PML) from reactivation of the John Cunnigham (JC) virus as a consequence of non-selective 41 inhibition. 14 Vedolizumab (VDZ) is a humanised, gut-selective monoclonal IgG1 antibody that targets the heterodimer α4β7 integrin, inhibiting migration and leukocytes adhesion. 15 The landmark trials GEMINI 1, 16 2, 17 and 3 18 showed that VDZ is effective in both CD and UC, with similar remission rates compared to anti-TNFs. 19 The long-term GEMINI safety studies and post hoc analyses confirmed an acceptable safety profile and efficacy, 20, 21 regardless previous exposure to anti-TNFs 22, 23 and age groups. 24 However, clinical trials do not necessarily reflect everyday practice, as real-life use may differ considerably in terms of patient selection. A number of real-life studies regarding VDZ have been published,
reporting novel -but sometimes conflicting -results, including possible clinical predictors of response and new safety signals. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The aim of this study was to describe our clinical experience with VDZ, defining its effectiveness and safety in inducing and maintaining remission in IBD patients treated in eight different hospitals across northern England.
Methods

Patients
Eight IBD centres (belonging to both university and general hospitals) from the UK disease extension for UC, and previous surgery. As third outcome, we looked at reasons for discontinuation, all the adverse events, infectious diseases, and other safety signals or disorders that were related to VDZ therapy that occurred from overall exposure to VDZ until end of follow-up. A sub-analysis of elderly patients (≥ 65 years old) was performed.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, Inc., California, USA). Non-parametric tests were used to analyse continuous variables, and absolute and relative frequencies to describe categorical variables. Categorical data were summarised as the percentage of the total group according to disease type (CD, UC).
Differences in continuous variables between two groups were analysed using the nonparametric Mann-Whitney U-test for unpaired samples (as not all variables were available in all patients). Chi-squared test was used for comparison of proportions. The degree of correlation between HBI or partial Mayo score and PGA (1=remission; 2=partial
response; 3=non-response or worsening) at 14 and 52 weeks was assessed with nonparametric two-tailed Spearman's rank correlation coefficient. Two-sided Fisher's exact test was used to compare categorical data between the two groups, along with the 95% confidence interval (CI) and odds ratio. A p-value of <0.05 was considered as statistically significant. Effectiveness outcomes for 14 weeks were reported on an intention-to-treat basis, while 52-week effectiveness data used the number of patients entered into maintenance therapy as the denominator.
Ethical standards
The study was performed as a clinical audit using routine collected clinical data and as such is exempt from the need for ethics committee approval in the UK and the need to take written informed consent. Steroid-free remission was particularly high in the studied population ( Figure 1 ). Figure 1 shows the 14-and 52-week response rates and steroid-free remission according to disease type and requires further effectiveness and safety data. In our cohort, we found a cumulative induction and maintenance response/remission rate for both CD and UC, generally higher than previous registration trials and in keeping with other long-term analyses. 16, 17, 20, 21 However, in our series UC patients experienced higher maintained response rates than The medical therapy of IBD poses a particular challenge in the elderly population that is more likely to suffer from multimorbidity with a higher risk of negative outcomes. We therefore sub-analysed the efficacy and safety of VDZ in the subgroup of patients ≥ 65
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years. VDZ proved to be effective, and no infectious diseases were reported. In a previous small case series of elderly patients, a few adverse events, including respiratory tract and gastrointestinal infections, were reported. 43 VDZ may represent a good choice for these patients, but more prospective studies are needed.
Additionally, we looked at potential predictors of clinical response (Supplementary Tables   2 and 3) according to the literature, 26, [27] [28] [29] 31, 32, 41, 42 but the analysis failed to demonstrate any statistical association. In contrast to post hoc GEMINI trials analyses being anti-TNF α naïve was not associated with a better response., 22, 23 Data from real-world series show conflicting results. 26, 27, 30, 31, 41 For CD our analysis may lack statistical power but for UC a greater proportion of patients were anti-TNFs naïve. Also, CRP and FC at baseline failed to discriminate patients who were more likely to achieve remission or response. A few realworld studies found a negative association between high disease activity and high CRP at baseline and clinical remission. 26, 27, 29, 33 Whether bridging steroid therapy and/or immunosuppressants increase VDZ response rate is still a matter of debate. Similar to the registration trials, 16, 17 the retrospective consortium study from the US, 31 and the Swedish National Registry 30 we found no association of concomitant immunosuppressants with response. In contrast, one retrospective analysis in CD patients reported that the addition of an immunomodulator after induction improved odds of clinical response at 52 weeks, acting as salvage therapy. 41 In The risk-benefit balance of immunomodulator therapy needs to be considered and as the majority of infections occurred in patients on combination therapy clinicians should routinely reevaluate the need for immunosuppressive therapy in patients on VDZ.
The role of dose escalation or intensification with VDZ remains unresolved. Five patients achieved remission after escalation of therapy (to six weekly in one patient and to four weekly in the others) and 13 CD patients had an additional dose at week 10. Data regarding dose escalation are still scanty, but this strategy proved efficacious in the longterm GEMINI studies. 20 ,21
Primary or secondary non-response were the leading causes (Table 2) for VDZ discontinuation (46/203, 22.6%), while six patients (2.9%) were not adherent to the planned VDZ infusions. This is the first report of non-adherence in patients treated with VDZ. Non-adherence to medication is an essential, though often underestimated, problem in IBD patients, where beliefs and concerns may have a negative impact. 44, 45 Overall, we encountered low rates of adverse events. Among these, five led to discontinuation (four urticarial rash and one supraventricular tachycardia during VDZ infusion). The cumulative incidence of non-infective adverse events of 5.1 per 100 personyear is much lower than that found in long-term GEMINI studies, 20,21 (we did not include disease progression as an adverse event however). We reported a relatively high occurrence of headache and paraesthesia, in keeping with other studies. 33, 46 The single case of miscarriage occurred in a 27-year old female with CD who had received 6 VDZ infusions and voluntarily decided to stop the infusions and subsequently flared. Pregnancy outcomes in patients treated with VDZ are still largely unknown. 42 Unsurprisingly, among the infectious diseases, nasopharyngitis and pneumonia were the most represented. We reported a cumulative incidence of infectious diseases of 11.9 per 100 person-year (13.7% of the whole cohort), that is comparable to the other real-life studies (range 1.7%-12.6%). 46 We reported two VDZ discontinuation in relation to significant viral infections in our cohort: a case of viral meningitis and a case of EpsteinBarr virus (EBV) infection with acute hepatitis. Both of these patients were on concomitant immunosuppressive therapy. A life-threatening case of fungal sepsis occurred in a 23-year old male who was on concomitant methotrexate and systemic steroid therapy. The only case of tuberculosis reactivation affecting the central nervous system occurred in a 57-year old female suffering from type 2 diabetes.
Our study has some limitations. First, the retrospective nature may lead to possible biases, such as the over-or underestimation of PGA. We tried to overcome this obstacle using a standardised spreadsheet with uniform data, also comprising HBI and partial Mayo score that showed a significant positive correlation with PGA. A similar method has already been used for the retrospective assessment of clinical efficacy of a biological therapy. 48 In summary, we have here described our 2-year long, real-life, multicentre experience with VDZ since it was approved for the treatment of IBD. Based on clinical and laboratory grounds, VDZ proved to be an effective and safe drug, even in this cohort of predominantly anti-TNF α exposed patients and in a subgroup of elderly patients.
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